Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of ...

Studies of the consequences of BAFF overexpression have been complemented by studies investigating the effects of blocking either BAFF or both BAFF and APRIL (a proliferation inducing ligand, also ...

Novartis also has an anti-APRIL antibody called zigakibart in phase 3 trials, while Vertex Pharma has a dual antagonist of BAFF and APRIL, povetacicept, which it acquired as part of its takeover ...

Aurinia Pharmaceuticals Inc (AUPH) reports a 24% revenue increase and significant cash flow improvements, while navigating patent challenges and advancing its drug pipeline.